Voyxact (sibeprenlimab-szsi, anti-APRIL mAb for IgA nephropathy)
Named-patient access overview. Voyxact is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Voyxact
Voyxact (sibeprenlimab-szsi) is a humanized IgG2 monoclonal antibody developed by Otsuka Pharmaceutical (originated at Visterra) for adults with primary IgA nephropathy at risk of disease progression. Sibeprenlimab binds and neutralizes APRIL (A PRoliferation-Inducing Ligand, also known as TNFSF13), a B-cell and plasma-cell cytokine that drives the production of pathogenic galactose-deficient IgA1, the immunoglobulin species at the root of IgA nephropathy.
Voyxact is administered by subcutaneous injection. By targeting the upstream APRIL axis on B cells and plasma cells, it works at a different point in the disease pathway than the available alternatives: sparsentan (RAAS and endothelin receptor blockade), iptacopan (alternative-pathway complement), and gut-targeted budesonide (Tarpeyo). Approval pathway, exact eGFR and proteinuria cutoffs, and full label population should be confirmed against the current FDA label for sibeprenlimab-szsi before prescribing.
For international patients, Voyxact is sourced by Reserve Meds from a DSCSA-compliant US specialty wholesaler with full serial traceability and may be accessible via Named Patient Program or personal-import pathways depending on destination country.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Voyxact
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Voyxact for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Voyxact is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Voyxact in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Voyxact
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.